Cornell E, Novikov D, Niu R, et al. - Researchers examined a total of 270 patients at 2 urban medical centers for patient demographics, comorbidities, hepatitis C virus (HCV) treatment, hepatic fibrosis status, surgical information, and postoperative complications. Individuals were classified into 2 groups based on their antiviral treatment status prior to total joint arthroplasty (TJA): Treated (n = 129) and Untreated (n = 141). Patients were divided into 2 groups based on their antiviral treatment status prior to TJA: Treated (n = 129) and Untreated (n = 141). Researchers applied Pearson’s chi-squared test, Student’s t-test, and multivariate logistic regressions to examine complications between groups. HCV antiviral treatment reduces postoperative complications after primary TJA, even among those who have progressed to hepatic fibrosis. The results considered that surgeons can use this information in shared decision making prior to TJA to counsel patients about the benefits of preoperative antiviral treatment even in the presence of hepatic fibrosis.